Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.

Abstract

Hyperglucagonemia contributes to hyperglycemia in patients with type 1 diabetes (T1D); however, novel therapeutics that block glucagon action could improve glycemic control. This phase 2 study evaluated the safety and efficacy of volagidemab, an antagonistic monoclonal glucagon receptor (GCGR) antibody, as an adjunct to insulin therapy in adults with T1D. The primary endpoint was change in daily insulin use at week 12. Secondary endpoints included changes in hemoglobin A1c (HbA1c) at week 13, in average daily blood glucose concentration and time within target range as assessed by continuous blood glucose monitoring (CGM) and seven-point glucose profile at week 12, incidence of hypoglycemic events, the proportion of subjects who achieve HbA1c reduction of ≥0.4%, volagidemab drug concentrations and incidence of anti-drug antibodies. Eligible participants (n = 79) were randomized to receive weekly subcutaneous injections of placebo, 35 mg volagidemab or 70 mg volagidemab. Volagidemab produced a reduction in total daily insulin use at week 12 (35 mg volagidemab: -7.59 units (U) (95% confidence interval (CI) -11.79, -3.39; P = 0.040 versus placebo); 70 mg volagidemab: -6.64 U (95% CI -10.99, -2.29; P = 0.084 versus placebo); placebo: -1.27 U (95% CI -5.4, 2.9)) without meeting the prespecified significance level (P < 0.025). At week 13, the placebo-corrected reduction in HbA1c percentage was -0.53 (95% CI -0.89 to -0.17, nominal P = 0.004) in the 35 mg volagidemab group and -0.49 (95% CI -0.85 to -0.12, nominal P = 0.010) in the 70 mg volagidemab group. No increase in hypoglycemia was observed with volagidemab therapy; however, increases in serum transaminases, low-density lipoprotein (LDL)-cholesterol and blood pressure were observed. Although the primary endpoint did not meet the prespecified significance level, we believe that the observed reduction in HbA1c and tolerable safety profile provide a rationale for further randomized studies to define the long-term efficacy and safety of volagidemab in patients with T1D.

• Authors: Jeremy Pettus, Schafer C Boeder, Mark P Christiansen, Douglas S Denham, Timothy S Bailey, Halis K Akturk, Leslie J Klaff, Julio Rosenstock, Mickie H M Cheng, Bruce W Bode, Edgar D Bautista, Ren Xu, Hai Yan, Dung Thai, Satish K Garg, Samuel Klein
• Journal: Nature medicine (Nat Med) Vol. 28 Issue 10 Pg. 2092-2099 (10 2022) ISSN: 1546-170X [Electronic] United States
• PMID: 36192552 (Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Chemical References

• Antibodies, Monoclonal, Humanized
• Blood Glucose
• Glycated Hemoglobin A
• Insulin
• Lipoproteins, LDL
• Receptors, Glucagon
• volagidemab
• Glucagon
• Transaminases

Topics

• Adult
• Antibodies, Monoclonal, Humanized (adverse effects)
• Blood Glucose
• Blood Glucose Self-Monitoring
• Diabetes Mellitus, Type 1 (drug therapy)
• Double-Blind Method
• Glucagon
• Glycated Hemoglobin (analysis, therapeutic use)
• Humans
• Insulin (therapeutic use)
• Lipoproteins, LDL (therapeutic use)
• Receptors, Glucagon (antagonists & inhibitors)
• Transaminases (therapeutic use)
• Treatment Outcome